secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-08-14T12:21:44+00:00
Accession:  0001193125-26-350568
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics Q2 2026: Net loss $75.5M, cash $116M, Orphai acquisition closed
--------------------------------------------------------------------------------

- Completed stock-for-stock Orphai acquisition adding LAM-001 inhaled rapamycin; concurrent $115M private placement, net $103.6M.
- Cash and equivalents $116M as of June 30, 2026, expected to fund operations through end of 2028.
- Net loss $75.5M ($12.31/share) vs $16.0M ($68.75/share) in Q2 2025; G&A up to $16.6M on one-time stock comp.
- Phase 2b PH-ILD data expected Q1 2028; BOS Phase 2 data Q1 2027; SAPH trial start late 2026.
- Phase 2a ATS data: 6MWD +67.4m, PVR -33.9% in PH-ILD patients; drug generally well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/0001193125-26-350568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer